Literature DB >> 11418594

The p42/p44 mitogen-activated protein kinase activation triggers p27Kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells.

C Delmas1, S Manenti, A Boudjelal, C Peyssonnaux, A Eychène, J M Darbon.   

Abstract

The p42/p44 mitogen-activated protein (MAP) kinase is stimulated by various mitogenic stimuli, and its sustained activation is necessary for cell cycle G(1) progression and G(1)/S transition. G(1) progression and G(1)/S transition also depend on sequential cyclin-dependent kinase (CDK) activation. Here, we demonstrate that MAP kinase inhibition leads to accumulation of the CDK inhibitor p27(Kip1) in NIH 3T3 cells. Blocking the proteasome-dependent degradation of p27(Kip1) impaired this accumulation, suggesting that MAP kinase does not act on p27(Kip1) protein synthesis. In the absence of extracellular signals (growth factors or cell adhesion), genetic activation of MAP kinase decreased the expression of p27(Kip1) as assessed by cotransfection experiments and by immunofluorescence detection. Importantly, MAP kinase activation also decreased the expression of a p27(Kip1) mutant, which cannot be phosphorylated by CDK2, suggesting that MAP kinase-dependent p27(Kip1) regulation is CDK2-independent. Accordingly, expression of dominant-negative CDK2 did not impair the down-regulation of p27(Kip1) induced by MAP kinase activation. These data demonstrate that the MAP kinase pathway regulates p27(Kip1) expression in fibroblasts essentially through a degradation mechanism, independently of p27(Kip1) phosphorylation by CDK2. This strengthens the role of this CDK inhibitor as a key effector of G(1) growth arrest, whose expression can be controlled by extracellular stimuli-dependent signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418594     DOI: 10.1074/jbc.M101714200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Growth inhibition by the muscarinic M(3) acetylcholine receptor: evidence for p21(Cip1/Waf1) involvement in G(1) arrest.

Authors:  Drew Burdon; Rajnikant Patel; R A John Challiss; Jonathan L Blank
Journal:  Biochem J       Date:  2002-10-15       Impact factor: 3.857

Review 2.  Extrinsic purinergic regulation of neural stem/progenitor cells: implications for CNS development and repair.

Authors:  Henning Ulrich; Maria P Abbracchio; Geoffrey Burnstock
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

3.  Attenuation of cell cycle regulator p27(Kip1) expression in vertebrate epithelial cells mediated by extracellular signals in vivo and in vitro.

Authors:  Anne-Katrin Rohlfing; Tillmann Schill; Christian Müller; Petra Hildebrandt; Alexandra Prowald; Jan-Peter Hildebrandt
Journal:  J Comp Physiol B       Date:  2005-10-26       Impact factor: 2.200

4.  ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets.

Authors:  Jessie Villanueva; Yuval Yung; Janice L Walker; Richard K Assoian
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

Review 5.  p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Authors:  Seth A Wander; Dekuang Zhao; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2010-10-21       Impact factor: 12.531

6.  14-3-3β Depletion Drives a Senescence Program in Glioblastoma Cells Through the ERK/SKP2/p27 Pathway.

Authors:  Sung Bin Seo; Je-Jung Lee; Hye Hyeon Yun; Chang-Nim Im; Yong-Sam Kim; Jeong-Heon Ko; Jeong-Hwa Lee
Journal:  Mol Neurobiol       Date:  2017-01-23       Impact factor: 5.590

7.  Erk 1,2 phosphorylates p27(Kip1): Functional evidence for a role in high glucose-induced hypertrophy of mesangial cells.

Authors:  G Wolf; R Reinking; G Zahner; R A K Stahl; S J Shankland
Journal:  Diabetologia       Date:  2003-07-10       Impact factor: 10.122

8.  Effects of mitofusin-2 gene on cell proliferation and chemotherapy sensitivity of MCF-7.

Authors:  Yun Xia; Yaqun Wu; Xiaojun He; Jianping Gong; Fazu Qiu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-05-15

9.  Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.

Authors:  Zhenyun Yang; Yiping Li; Fuqin Yin; Rebecca J Chan
Journal:  Exp Hematol       Date:  2008-07-21       Impact factor: 3.084

Review 10.  That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.

Authors:  Matthew J Sale; Simon J Cook
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.